Danaher completes acquisition of Masimo, expanding diagnostics portfolio
Danaher (NYSE:DHR), a global science and technology innovator, announced that it has completed the acquisition of Masimo (NASDAQ:MASI), a specialty diagnostics provider known for pulse oximetry and other patient monitoring solutions in acute care settings.
As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher, and Masimo common stock has ceased trading on the Nasdaq Stock Market.
The company will continue to operate under the Masimo brand as a stand-alone operating company within Danaher’s Diagnostics segment, leveraging its advanced sensor technology and AI-enabled patient monitoring to complement Danaher’s existing portfolio.
Consideration payable to former Masimo stockholders will follow the terms of the merger agreement as detailed in SEC filings.
Regarding financial guidance, Danaher said its previously communicated Q2 and full-year 2026 guidance remains unchanged, excluding Masimo’s expected contribution.
The company does not anticipate a material contribution from Masimo in Q2 2026 but plans to update full-year guidance to reflect Masimo’s impact in connection with its second-quarter earnings release.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
